SOCMA Raises Concern over TSCA Reform - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SOCMA Raises Concern over TSCA Reform


ePT--the Electronic Newsletter of Pharmaceutical Technology

Legislative efforts to modernize provisions in the Toxic Substances Control Act of 1976 (TSCA) that involve chemical safety and reporting requirements is drawing criticism from the chemical industry. The Society of Chemical Manufacturers and Affiliates (SOCMA) raised concerns over one bill, the Toxic Chemicals Safety Act of 2010 (HR 5820), in a Congressional hearing last week. SOCMA is the US trade association representing custom and batch manufacturers, including contract manufacturers of active pharmaceutical ingredients and intermediates.

TSCA provides the US Environmental Protection Agency with authority to require reporting, record-keeping and testing requirements, and restrictions relating to chemical substances and/or mixtures. Certain substances are generally excluded from TSCA, including food, drugs, cosmetics, and pesticides. Although there is general agreement between business groups and environmental groups that TSCA needs to be modernized, there is debate over specific legislative proposals.  

In testimony before the US House Subcommittee on Commerce, Trade, and Consumer Protection, Beth D. Bosley, president of Boron Specialties (Valencia, PA) and representing SOCMA, said the recently introduced legislation, the Toxic Chemicals Safety Act of 2010, poses “overwhelming challenges for batch, custom, and specialty chemical manufacturers,” according to a SOCMA press release. Although Bosley noted some improvements in the bill, including the requirement for varied and tiered testing, she expressed concern over the economic impact of the bill.

“It is more important than ever that we maintain our competitive edge as innovators,” Bosley stated. “The US chemical industry’s competitiveness has continued to decrease substantially in recent years due to competition from countries, like China and India, with lower resource costs, lower wage standards, and a less burdensome regulatory environment.”

SOCMA highlighted several major concerns with the legislation. First, it said that the bill applies “inappropriate safety standards” by regulating industrial chemicals similar to standards used to regulate drugs and foods, which would create market barriers for low-risk chemicals. SOCMA also objects to new chemical and use requirements, which it contends involve an “unnecessary” increase in testing and reporting, thereby discouraging research and development and the introduction of new chemicals or new applications of existing chemicals into the market.

The association also objects to the inclusion of mixtures in reporting requirements, citing that it would increase the level of reporting for chemical mixtures that do not have an identified risk. SOCMA also says that the disclosure requirements do not adequately protect confidential business information and that the bill does not provide for state preemption, thereby causing a potential disruption in interstate commerce.

SOCMA said it “looks forward to continuing its efforts to promote recommendations for a pragmatic approach to TSCA reform with members of Congress,” according to the organization's press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here